

Duravest, Inc.
1040 S. Milwaukee Ave., Suite 250
Wheeling (Chicago), IL 60090, USA
Tel.: +1 847 791 5677
Fax: +1 847 520 3037
Email: info@duravestinc.com



CURRENT INVESTMENTS

Estracure, Inc.

Estracure is a Montreal-based company currently developing next-generation coronary stenting products based on proprietary estrogen-based technologies that minimize restenosis and potentially prevent progression of coronary lesions. With safety an increasingly important consideration with drug-eluting stents, Estracure's novel technology with its enhanced safety profile holds promise as a potential replacement for current-generation drug-eluting stents.

Estracure Inc.

Research Centre
Montreal Heart Institute
5000, Bélanger St. East
Montreal, Quebec
Canada H1T 1C8



B.M.T.S. Inc.

B.M.T.S. owns the intellectual rights to use the Pulsed-Signal-Therapy. The therapy is dedicated to the safe, non-invasive treatment of osteoarthritis, osteoporosis and orthopedic injuries and associated pain management. The Pulsed-Signal-Therapy is marketed by the German company PST GmbH. B.M.T.S. fits in with Duravest's mission of developing technologies that have a strong basis in safety as well as in cross-disciplinary areas that fall in between traditional medical technology sectors. Veterinary applications of the technology (PST-VET) are also being offered in the U.S.

B.M.T.S., Inc.

1040 S. Milwaukee Ave. Suite 250
Wheeling (Chicago), IL 60090, USA
Tel.: +1 847 791 5677
Fax: +1 847 520 3037
Email: info@duravestinc.com

